Expand HNSCC TIL + pembrolizumab cohort in basket study
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- November 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“HNSCC: Expanding the HNSCC TIL + pembrolizumab in basket study”
What we found
Evidence strength A What the grades mean
The company confirmed the existence and ongoing activity of the HNSCC TIL plus pembrolizumab cohort (Cohort 2A) within the IOV-COM-202 basket study, presenting updated results for this cohort in November 2021.
-
A Iovance Biotherapeutics, Inc. 10-Q filed 2022-05-05
“In Cohort 2A of the IOV-COM-202 trial, we are enrolling advanced, recurrent, or metastatic HNSCC patients who are naïve to prior immunotherapy including anti-PD-1/anti-PD-L1 therapy. The patients receive LN-145 in combination with pembrolizumab.” ✓ confirmed on the page
-
A Iovance Biotherapeutics, Inc. 10-Q filed 2022-11-03
“Our oral presentation of TIL therapy plus pembrolizumab at SITC in November 2021 also included updated results in HNSCC patients from Cohort 2A in IOV-COM-202” ✓ confirmed on the page
Market reaction: the shares moved -13.6% against the S&P 500 over the three sessions around the disclosure (4 May 2022 to 9 May 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Rollout
- Indicative materiality
- Low rules
- Action
- Expand
- Deliverable
- Expanded HNSCC TIL + pembrolizumab cohort
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Iovance Biotherapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IOVA-021228 · Corrections policy